+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Smoking Cessation Aids Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4617265
  • Report
  • April 2019
  • Region: Global
  • 115 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • NJOY
  • MORE
Market Overview

Smoking is one of the major causes of lung cancer and other respiratory and cardiac diseases. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapy. Awareness through digital media, print media and other sources of information has proved to be effective in curbing nicotine addiction crisis to some extent. According to CDC, in 2017, 14 of every 100 US adults aged 18 years or older (14.0%) currently smoke cigarettes. This hints at a high usage of de-addiction products. Also, this depicts the growing awareness of the people and their readiness to quit smoking. Also, there are non-government and government establishments working to educate and help people quit smoking that are engaged dedicatedly, to bring the number of smokers down. For instance, in 2017, the US Food and Drug Administration launched an adult smoking cessation education campaign aimed at encouraging cigarette smokers to quit smoking. Other factors that will help the market growth during the forecast period, include the introduction of new products and reimbursement for smoking cessation therapy. However, the adverse effect of drugs is one the challenge that drug therapy market for Smoking cessation has witnessed.

Scope of the Report

Tobacco use can lead to tobacco/nicotine dependence and serious health problems. Quitting smoking greatly reduces the risk of developing smoking-related diseases. Tobacco/nicotine dependence is a condition that often requires repeated treatments, but there are helpful treatments and resources for quitting. Tobacco smoke contains a deadly mix of more than 7,000 chemicals; hundreds are harmful, and about 70 can cause cancer. Smoking increases the risk of serious health problems, many diseases, and death. People who stop smoking greatly reduce their risk of disease and early death.

Key Market Trends

E-cigarettes Technology Expected to Lead the Market

The smoking cessation aids market is segmented have been segmented Products, End User and Geography. Product segment is further segmented into Nicotine Replacement Therapy, Drugs and electronic cigarettes.

E-cigarettes are an effective alternative for reducing health conditions associated with tobacco, while nicotine replacement therapies work best for smoking cessation. E-cigarettes are a potential threat to tobacco-based cigarettes. At the same time, an opportunity for tobacco manufacturers to enter the new emerging segment catering to the smoking population. consumption of e-cigarettes are less harmful compared to the regular cigarettes, no smoke and thus no risk of passive smoking, allowed to use even in no-smoking places, varying nicotine levels and availability in various flavors are some of the major driving factors for e-cigarettes market.

Asia-Pacific Expected to Show Fastest Growth over the Forecast Period

Asia-Pacific is expected to be the fastest growing region for the market, due to increasing awareness about the smoking cessation and nicotine de-addiction products and a huge population base in the area. In a study called Tobacco Smoking and Mortality in Asia published by JAMA Network March 2019, A Pooled Meta-analysis, an international collaboration of researchers, led by those from Vanderbilt University, USA, have studied the trends in tobacco use in China, Japan, South Korea, Singapore, Taiwan, and India. It was estimated that 8.3 million deaths will be attributed to smoking by 2030, half of the world's male smokers live in China, India, and Indonesia and Asia is the world's largest tobacco consumer and producer.

Competitive Landscape

The market players in the global Smoking Cessation Aids market involves various growth strategies such as collaborations, partnerships, agreements, mergers and acquisitions in order to enhance the market presence. For instance, in February 2019, Antidote Therapeutics Announces Collaboration with the National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody, for reducing Lung Cancer in High-Risk Smokers. Furthermore, the introduction of new products, collaborations with government and NGO's to create awareness of smoking cessation also boosts the market growth. For instance, in October 2018, Philip Morris has launched a campaign encouraging people to stop smoking, with ads in several UK newspapers. In January 2015, in Germany McNeil launched QuickMist, a fast-acting nicotine spray that replaces tobacco and supports the victim.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • NJOY
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Large Population Addicted to Smoking
4.2.2 Awareness on Hazards of Smoking
4.2.3 Banning Advertisements of Tobacco Products
4.3 Market Restraints
4.3.1 Adverse effects of Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Product
5.1.1 Nicotine Replacement Therapy
5.1.1.1 NRT Gum
5.1.1.2 NRT lozenges
5.1.1.3 NRT Inhalers
5.1.1.4 NRT Patches
5.1.1.5 Sprays
5.1.2 Drugs
5.1.3 Electronic Ciggarettes
5.1.4 Others
5.2 End User
5.2.1 Hospital Pharmacies
5.2.2 Online Channel
5.2.3 Retail Pharmacies
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Reckitt Benckiser Plc
6.1.2 Pfizer
6.1.3 GlaxoSmithKline Plc
6.1.4 F. Hoffmann-La Roche AG
6.1.5 Novartis
6.1.6 Johnson and Johnson
6.1.7 Bayer AG
6.1.8 Cipla Ltd.
6.1.9 Takeda Pharmaceuticals Co. Ltd.
6.1.10 NJOY

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Reckitt Benckiser Plc
  • Pfizer
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche AG
  • Novartis
  • Johnson and Johnson
  • Bayer AG
  • Cipla Ltd.
  • Takeda Pharmaceuticals Co. Ltd.
  • NJOY
Note: Product cover images may vary from those shown
Adroll
adroll